Journal Article Review Epublish 27 citations
PubMed: 36769359 DOI: 10.3390/ijms24033037
Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors and Iron Metabolism.
Int J Mol Sci 24(3)
Authors: Chie Ogawa, Ken Tsuchiya, Kunimi Maeda
Affiliations
- Maeda Institute of Renal Research, Kawasaki 211-0063, Japan.
- Biomarker Society, INC, Kawasaki 211-0063, Japan.
- Department of Blood Purification, Tokyo Women's Medical University, Tokyo 162-8666, Japan.
- Maeda Institute of Renal Research, Kawasaki 211-0063, Japan. Biomarker Society, INC, Kawasaki 211-0063, Japan.
Abstract
The production of erythropoietin (EPO), the main regulator of erythroid differentiation, is regulated by hypoxia-inducible factor (HIF). HIF2α seems to be the principal regulator of EPO transcription, but HIF1α and 3α also may have additional influences on erythroid maturation. HIF is also involved in the regulation of iron, an essential component in erythropoiesis. Iron is essential for the organism but is also highly toxic, so its absorption and retention are strictly controlled. HIF also induces the synthesis of proteins involved in iron regulation, thereby ensuring the availability of iron necessary for hematopoiesis. Iron is a major component of hemoglobin and is also involved in erythrocyte differentiation and proliferation and in the regulation of HIF. Renal anemia is a condition in which there is a lack of stimulation of EPO synthesis due to decreased HIF expression. HIF prolyl hydroxylase inhibitors (HIF-PHIs) stabilize HIF and thereby allow it to be potent under normoxic conditions. Therefore, unlike erythropoiesis-stimulating agents, HIF-PHI may enhance iron absorption from the intestinal tract and iron supply from reticuloendothelial macrophages and hepatocytes into the plasma, thus facilitating the availability of iron for hematopoiesis. The only HIF-PHI currently on the market worldwide is roxadustat, but in Japan, five products are available. Clinical studies to date in Japan have also shown that HIF-PHIs not only promote hematopoiesis, but also decrease hepcidin, the main regulator of iron metabolism, and increase the total iron-binding capacity (TIBC), which indicates the iron transport capacity. However, concerns about the systemic effects of HIF-PHIs have not been completely dispelled, warranting further careful monitoring.
MeSH
Hematopoiesis, Prolyl-Hydroxylase Inhibitors, Prolyl Hydroxylases, Erythropoiesis, Hypoxia, Absorption, Mixed Function Oxygenases, Procollagen-Proline Dioxygenase
Cited by
- Elucidating the Role of HIF-1α/YAP Signaling Pathway in Regulating Inflammation in Human Periodontal Stem Cells: An in vitro Study. J Inflamm Res, 2025
- Erythrocyte indices and response to hypoxia-inducible factor prolyl hydroxylase inhibitors in chronic kidney disease patients with renal anemia: a retrospective study. BMC Nephrol, 2024
- Influencing factors of clinical efficacy of roxadustat among hemodialysis patients. Ren Fail, 2024
- Tubular Endogenous Erythropoietin Protects Renal Function against Ischemic Reperfusion Injury. Int J Mol Sci, 2024
- HIF-PH inhibitors induce pseudohypoxia in T cells and suppress the growth of microsatellite stable colorectal cancer by enhancing antitumor immune responses. Cancer Immunol Immunother, 2025
- Hypoxia-induced conversion of sensory Schwann cells into repair cells is regulated by HDAC8. Nat Commun, 2025